Samsung BioLogics’ $1.97 Billion Initial Public Offering

Simpson Thacher represented the underwriters, led by Citigroup Global Markets Korea Securities, Korea Investment & Securities, Credit Suisse Securities, J.P. Morgan Securities, NH Investment & Securities and Samsung Securities, in the initial public offering of Samsung BioLogics Co., Ltd. (“Samsung BioLogics”), a biologics contract manufacturing company based in Korea. The offering raised Won 2.25 trillion (approximately US$1.97 billion) for the issuer and the selling shareholder, Samsung Electronics Co., Ltd.

The offering marks the largest equity deal in South Korea since 2010 and the largest ever in the biopharmaceutical industry in Asia. The common shares of Samsung BioLogics were listed on the KRX KOSPI Market of the Korea Exchange under the code 207940. The common shares were offered by Samsung BioLogics and the selling shareholder as a registered IPO in Korea and in reliance on exemptions under the U.S. Securities Act of 1933, as amended, including Rule 144A and Regulation S, outside Korea.

Samsung BioLogics is one of the world’s fastest growing companies in the large-scale biologics contract manufacturing industry. Samsung BioLogics also engages in the development and commercialization of biosimilar drugs through its joint ventures.

The Simpson Thacher team for the transaction included Youngjin Sohn (Picture), Iksoo Kim and Joongwon Park (Corporate – Seoul); and Rob Holo and Sarah Katz (Tax).

Involved fees earner: Youngjin Sohn – Simpson Thacher & Bartlett; Iksoo Kim – Simpson Thacher & Bartlett; Joongwon Park – Simpson Thacher & Bartlett; Robert Holo – Simpson Thacher & Bartlett;

Law Firms: Simpson Thacher & Bartlett;

Clients: Citigroup Global Markets Ltd; Credit Suisse Securities Limited; JP Morgan Securities; NH Investment Securities Co., Ltd.; Samsung Securities; Korea Investment & Securities Co., Ltd.;


Author: Michael Patrini